Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Bionik Laboratories Corp. | v426047_ex99-1.htm |
| UNITED STATES |
| SECURITIES AND EXCHANGE COMMISSION |
| Washington, DC 20549 |
| FORM 8-K |
| CURRENT REPORT Pursuant |
| to Section 13 or 15(d) of the |
| Securities Exchange Act of 1934 |
| Date of report (Date of earliest event reported): November 27, 2015 |
|
Bionik Laboratories Corp. |
| (Exact Name of Registrant as Specified in Its Charter) |
| Delaware | 000-54717 | 27-1340346 | ||
| (State or Other Jurisdiction of Incorporation or Organization) | (Commission File Number) | (IRS Employer Identification No.) |
|
483 Bay Street, N105 Toronto, ON |
M5G 2C9 | |
|
(Address of Principal Executive Offices)
|
(Zip Code) | |
| Registrant’s Telephone Number, Including Area Code: (416) 640-7887 | ||
|
| ||
| (Former Name or Former Address, if Changed Since Last Report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
On November 27, 2015, the Board of Directors of Bionik Laboratories Corp. (the “Company”) granted Leslie Markow, the Company’s Chief Financial Officer, options under the Company’s 2014 Equity Incentive Plan to purchase 400,000 shares of the Company’s common stock. Such options are exercisable at $1.22 per share, being the closing price of the Company’s common stock on the day prior to the grant date. These options have a term of seven years and provide for vesting of 133,333 on November 27, 2016, 133,333 on November 27, 2017 and 133,334 on November 27, 2018.
| Item 7.01 | Regulation FD Disclosure |
On December 2-3, 2015, the Company will make a presentation and participate in conferences with investors during the LD Micro Main Event in Los Angeles, California. A copy of the Company’s presentation materials is attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2. of Form 8-K, this information, including the Exhibit, is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD, and shall not be deemed to be incorporated by reference into any of the Company’s filings under the Securities Act or the Exchange Act whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.
| Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits
| Exhibit No. | Description |
| 99.1 | Presentation |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: December 3, 2015
| BIONIK LABORATORIES CORP. | ||
| By: | /s/ Leslie Markow | |
| Name: | Leslie Markow | |
| Title: | Chief Financial Officer | |
3